Phase 1 N=7 Exposure Therapy for Veterans With PTSD and Panic Attacks (Phase 1)
PTSD · Panic Attacks
Primary: Clinician Administered PTSD Scale (CAPS) — 29.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects
Epilepsy
Primary: Simvastatin Cmax (Maximum Plasma Concentration) — 17.7; 6.89 ng/mL
Phase 1 N=56 Effect of Footwear on the Clinical, Functional, and Biomechanical Aspects in Elderly Women With Knee Osteoarthritis (OA)
Knee Osteoarthritis
Primary: Western Ontario and McMaster Universities (WOMAC) Pain Subscale — 9.2; 10.0; 4.5; 6.6 score — p=0.006
Phase 1 N=50 Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Number of Participants With Abnormal Physical Examination Findings
Phase 1 N=40 Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax - Maximum Plasma Concentration — 6461; 13183; 6547; 12988 ng/ml
Phase 1 N=17 An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093
Epilepsy
Primary: Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast). — 954.891; 49.750; 240188.369; 234750.429 h·ng/mL
Phase 1 N=4 Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
Parkinson Disease
Primary: Maximum Plasma Concentration (Cmax) — 482.98 ng-eq/mL
Phase 1 N=140 A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
Healthy
Primary: Number of Participants With Injection Site Reactions Following Either Vaccine Dose Worst Severity Reported — 25; 25; 24; 21 participants
Phase 1 N=34 Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
Parkinson's Disease (PD)
Primary: Number of Patients With at Least One Adverse Event — 3; 1; 1; 2 Number of patients
Phase 1 N=12 Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
Parkinson
Primary: Cmax - Maximum Observed Plasma Concentration — 635.0; 238.2 ng/mL
Phase 1 N=18 Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax (BIA 2-005) — 10973; 11044; 11022 ng/mL
Phase 1 N=64 A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
Parkinson Disease
Primary: Adverse Events (AEs) — 0; 0; 2; 0 Number of Adverse Events
Phase 1 N=43 Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine
Epilepsy
Primary: Cmax (BIA 2-093) - the Maximum Plasma Concentration — 18601; 14591 ng/mL
Phase 1 N=13 Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
Epilepsy
Primary: Maximum Drug Concentration (Cmax) — 15753; 5978; 428; 1708 ng/mL
Phase 1 N=63 A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
Malaria Falciparum · Malaria Vivax · Healthy Volunteers
Primary: Adverse Events — 1; 0; 2; 0 participants